ArticleAnnals of general psychiatry2025
Vortioxetine effectiveness in the treated major depressive disorder patients in Saudi Arabia.
Article in Annals of general psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor Depressive Disorder (MDD) is a prevalent mental health condition characterized by persistent feelings of sadness, loss of interest or pleasure, and a range of physical and cognitive symptoms. Despite the availability of various treatment options, many MDD patients continue to experience significant impairment in their daily lives. PURPOSE: This multicenter study aimed to evaluate the therapeutic benefits of vortioxetine in routine clinical practice for patients with MDD in Saudi Arabia.
methodsA total of 499 eligible patients participated in the study. This is a Phase IV study that included 30 psychiatric sites across Saudi Arabia. Data collection occurred at baseline and routine visits. Patients treated with vortioxetine experienced a significant reduction in depressive symptom severity, as indicated by the PHQ-9 total score, throughout the study period (p < 0.001).
resultsSignificant improvements were also observed in various areas of functioning and cognitive depression symptoms, and safety. Results demonstrated a significant reduction in depressive symptoms, and sexual well-being, indicating vortioxetine as an effective treatment option for MDD in the Middle East and Africa (MEA) region.
conclusionsThese findings support the real-world effectiveness of vortioxetine as a promising treatment option for MDD patients in the MEA region, highlighting its potential to reduce depressive symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.